About Furiex Pharmaceuticals (NASDAQ:FURX)
Furiex Pharmaceuticals, Inc. is a drug development collaboration company. The Company's product pipeline includes two marketed products and three programs in development, including late-stage compounds, in multiple therapeutic areas. Its programs include Priligy, Alogliptin Nesina, Alogliptin/Actose Combination, Alogliptin/Metformin Combination, Fluoroquinolone, Mu Delta and PPD 10558. In November 2011, it acquired full exclusive license rights to develop and commercialize the compound MuDelta under its existing development and license agreement with Janssen Pharmaceutica N.V. Effective July 2, 2014 Forest Laboratories Inc, a unit of Actavis PLC, acquired the entire share capital of Furiex Pharmaceuticals Inc.
Industry, Sector and Symbol
Industry Life Sciences Tools & Services
Sub-IndustryLife Sciences Tools & Services
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on EquityN/A
Return on AssetsN/A
Furiex Pharmaceuticals (NASDAQ:FURX) Frequently Asked Questions
What is Furiex Pharmaceuticals' stock symbol?
Furiex Pharmaceuticals trades on the NASDAQ under the ticker symbol "FURX."
Who are some of Furiex Pharmaceuticals' key competitors?
Some companies that are related to Furiex Pharmaceuticals include Roche (ROG), Sanofi (SAN), Bayer (BAYN), CSL (CSL), GlaxoSmithKline (GSK), AstraZeneca (AZN), Covidien (COV), Beximco Pharmaceuticals (BXP), Shire (SHP), Essilor International (EI), C R Bard (BCR), Medivation (MDVN), Ramsay Health Care (RHC), CareFusion (CFN), AEGON (AGN), Bioverativ (BIVV), Cochlear (COH) and Salix Pharmaceuticals (SLXP).
Has Furiex Pharmaceuticals been receiving favorable news coverage?
Media coverage about FURX stock has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm scores the sentiment of press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Furiex Pharmaceuticals earned a media sentiment score of 0.19 on Accern's scale. They also gave news stories about the healthcare company an impact score of 45.61 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near term.
How do I buy shares of Furiex Pharmaceuticals?
Shares of FURX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How can I contact Furiex Pharmaceuticals?
Furiex Pharmaceuticals' mailing address is 3900 Paramount Pkwy Ste 150, MORRISVILLE, NC 27560-5401, United States. The healthcare company can be reached via phone at +1-919-4567800.
MarketBeat Community Rating for Furiex Pharmaceuticals (FURX)MarketBeat's community ratings are surveys of what our community members think about Furiex Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Furiex Pharmaceuticals (NASDAQ:FURX) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
Furiex Pharmaceuticals (NASDAQ:FURX) Earnings History and Estimates Chart
Furiex Pharmaceuticals (NASDAQ FURX) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/7/2014||Q114||($0.63)||($1.25)||$10.01 million||$6.40 million||View||N/A|
|3/11/2014||Q413||($1.06)||($0.63)||$12.80 million||$13.10 million||View||N/A|
|11/5/2013||Q3 2013||($1.33)||($0.85)||$21.30 million||$15.55 million||View||N/A|
|8/6/2013||Q2 2013||($1.65)||($2.32)||$11.94 million||$3.00 million||View||N/A|
|5/7/2013||Q1 2013||$0.70||$0.82||$33.42 million||$39.33 million||View||N/A|
|3/6/2013||Q4 2012||($2.04)||($0.90)||$7.43 million||$9.21 billion||View||N/A|
Furiex Pharmaceuticals (NASDAQ:FURX) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Furiex Pharmaceuticals (NASDAQ:FURX)
No dividend announcements for this company have been tracked by MarketBeat.com
Furiex Pharmaceuticals (NASDAQ FURX) Insider Trading and Institutional Ownership History
Furiex Pharmaceuticals (NASDAQ FURX) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|6/24/2014||Paul S Covington||VP||Sell||10,368||$104.12||$1,079,516.16|| |
|6/24/2014||Sailash Patel||CFO||Sell||32,928||$104.00||$3,424,512.00|| |
|6/18/2014||Paul S Covington||VP||Sell||45,691||$104.11||$4,756,890.01|| |
|6/17/2014||Gail Frances Mcintyre||SVP||Sell||74,457||$105.01||$7,818,729.57|| |
|6/13/2014||Paul S Covington||VP||Sell||3,228||$104.25||$336,519.00|| |
|6/10/2014||Gail Frances Mcintyre||SVP||Sell||1,746||$104.58||$182,596.68|| |
|6/10/2014||Paul S Covington||VP||Sell||2,872||$104.63||$300,497.36|| |
|6/10/2014||Sailash Patel||CFO||Sell||1,504||$104.68||$157,438.72|| |
|9/10/2013||Paul S Covington||VP||Sell||30,000||$40.89||$1,226,700.00|| |
|8/9/2013||Peter Corr||Director||Sell||7,500||$39.74||$298,050.00||3,580|| |
|7/19/2013||Gail Frances Mcintyre||SVP||Sell||10,581||$40.00||$423,240.00|| |
|3/12/2013||Stephen W Kaldor||Director||Sell||6,352||$41.58||$264,116.16|| |
|8/15/2012||June Sherie Almenoff||President||Buy||1,000||$18.67||$18,670.00|| |
Furiex Pharmaceuticals (NASDAQ FURX) News Headlines
No headlines for this company have been tracked by MarketBeat.com
Furiex Pharmaceuticals (NASDAQ:FURX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Furiex Pharmaceuticals (NASDAQ:FURX) Income Statement, Balance Sheet and Cash Flow Statement
Furiex Pharmaceuticals (NASDAQ FURX) Stock Chart for Monday, March, 19, 2018